Lenoir, NC February 6, 2023 – Exela Pharma Sciences, LLC (“Exela”) has commenced patent infringement litigation today against Nivagen Pharmaceuticals, Inc. (“Nivagen”) in the United States District Court for the District of Delaware to prevent unauthorized launch of its recently approved 7.25% L-Cysteine injection drug product. Exela believes Nivagen’s product infringes one or more of Exela’s patents covering Exela’s pioneering work in developing low-aluminum L-Cysteine injection products. Exela seeks among other remedies a temporary restraining order and an injunction. About Exela Pharma SciencesExela Pharma Sciences, a fast-growing US based integrated specialty pharmaceutical company, focuses on developing, manufacturing and marketing proprietary
Read More